Levinson SS. Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test.
Clin Chim Acta 2005;
356:1-8. [PMID:
15936299 DOI:
10.1016/j.cccn.2004.12.021]
[Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2004] [Revised: 11/04/2004] [Accepted: 12/23/2004] [Indexed: 11/26/2022]
Abstract
BACKGROUND
Inflammation appears to be an important ingredient in the process of atherosclerosis that leads to coronary artery disease. Some have designed an algorithm for assessing risk of coronary artery disease using the inflammatory marker hs-CRP in conjunction with lipoprotein lipid risk factors.
AIM
I contend that because of its poor discrimination for coronary risk in clinical trials, until its utility is better proven, hs-CRP should not be recommended for defining risk.
REVIEW
Published articles and reassessment of papers previously published.
CONCLUSIONS
After adjustment for conventional risk factors, hs-CRP discriminates poorly between persons with coronary disease and those without over a range of from about 0.6 to 7 mg/L which includes most apparently well people. Nor does the evidence indicate that hs-CRP adds significant predictive value to the clinical traits that define metabolic syndrome.
Collapse